Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papilloma virus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers, with an ongoing Phase II dose escalation clinical trial evaluating first-line treatment of choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer.